Calcifediol is superior to cholecalciferol in improving vitamin D status in postmenopausal women: a randomized trial.


Journal

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640

Informations de publication

Date de publication:
10 2021
Historique:
revised: 31 05 2021
received: 22 02 2021
accepted: 02 06 2021
pubmed: 9 6 2021
medline: 27 10 2021
entrez: 8 6 2021
Statut: ppublish

Résumé

Vitamin D has shown to play a role in multiple diseases due to its skeletal and extraskeletal actions. Furthermore, vitamin D deficiency has become a worldwide health issue. Few supplementation guidelines mention calcifediol treatment, despite being the direct precursor of calcitriol and the biomarker of vitamin D status. This 1-year, phase III-IV, double-blind, randomized, controlled, multicenter clinical trial assessed the efficacy and safety of calcifediol 0.266 mg soft capsules in vitamin D-deficient postmenopausal women, compared to cholecalciferol. Results reported here are from a prespecified interim analysis, for the evaluation of the study's primary endpoint: the percentage of patients with serum 25-hydroxyvitamin D (25(OH)D) levels above 30 ng/ml after 4 months. A total of 303 patients were enrolled, of whom 298 were included in the intention-to-treat (ITT) population. Patients with baseline levels of serum 25(OH)D <20 ng/ml were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months, calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months, and cholecalciferol 25,000 IU/month for 12 months. At month 4, 35.0% of postmenopausal women treated with calcifediol and 8.2% of those treated with cholecalciferol reached serum 25(OH)D levels above 30 ng/ml (p < 0.0001). The most remarkable difference between both drugs in terms of mean change in serum 25(OH)D levels was observed after the first month of treatment (mean ± standard deviation change = 9.7 ± 6.7 and 5.1 ± 3.5 ng/ml in patients treated with calcifediol and cholecalciferol, respectively). No relevant treatment-related safety issues were reported in any of the groups studied. These results thus confirm that calcifediol is effective, faster, and more potent than cholecalciferol in raising serum 25(OH)D levels and is a valuable option for the treatment of vitamin D deficiency. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Identifiants

pubmed: 34101900
doi: 10.1002/jbmr.4387
pmc: PMC8597097
doi:

Substances chimiques

Vitamin D 1406-16-2
Cholecalciferol 1C6V77QF41
Calcifediol P6YZ13C99Q

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1967-1978

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Références

J Clin Endocrinol Metab. 2011 Apr;96(4):981-8
pubmed: 21289249
Curr Med Res Opin. 2013 Apr;29(4):305-13
pubmed: 23320612
J Bone Miner Res. 2011 Jul;26(7):1609-16
pubmed: 21416506
Curr Med Res Opin. 2013 Nov;29(11):1565-72
pubmed: 24020910
J Clin Endocrinol Metab. 2008 Sep;93(9):3430-5
pubmed: 18544622
Osteoporos Int. 2019 Jan;30(1):3-44
pubmed: 30324412
Endocrine. 2015 Sep;50(1):12-26
pubmed: 25931412
J Steroid Biochem Mol Biol. 2016 Nov;164:205-208
pubmed: 26829558
Front Endocrinol (Lausanne). 2019 May 28;10:317
pubmed: 31191450
Br J Nutr. 2014 Jan 14;111(1):23-45
pubmed: 23930771
Eur J Clin Nutr. 2020 Feb;74(2):231-247
pubmed: 31907366
J Bone Miner Res. 2012 Apr;27(4):817-24
pubmed: 22161773
Osteoporos Int. 2018 Aug;29(8):1697-1711
pubmed: 29713796
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
Calcif Tissue Int. 2020 Jan;106(1):14-29
pubmed: 31069443
Am J Clin Nutr. 2008 Jun;87(6):1738-42
pubmed: 18541563
BMC Musculoskelet Disord. 2020 Mar 12;21(1):164
pubmed: 32164704
Clin Chem. 2008 Jan;54(1):188-96
pubmed: 17998267
Osteoporos Int. 2017 Mar;28(3):775-780
pubmed: 28028554
Rev Clin Esp (Barc). 2015 Dec;215(9):515-26
pubmed: 26434811
Nutrients. 2019 Nov 15;11(11):
pubmed: 31731651
J Steroid Biochem Mol Biol. 2020 Sep;202:105719
pubmed: 32535032
J AOAC Int. 2017 Sep 1;100(5):1323-1327
pubmed: 28492133
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Steroid Biochem Mol Biol. 2018 Jan;175:125-135
pubmed: 28216084
Endocrinol Metab Clin North Am. 2017 Dec;46(4):901-918
pubmed: 29080642
Endocr Rev. 2019 Aug 1;40(4):1109-1151
pubmed: 30321335
J AOAC Int. 2017 Sep 1;100(5):1318-1322
pubmed: 28492143
Osteoporos Int. 2017 Nov;28(11):3239-3249
pubmed: 28815282
Osteoporos Int. 2015 Jan;26(1):373-81
pubmed: 25369890
Clin Chem Lab Med. 2004 Jan;42(1):90-5
pubmed: 15061387
Age Ageing. 2014 Sep;43(5):592-5
pubmed: 25074538
Adv Nutr. 2017 Nov 15;8(6):947-957
pubmed: 29141976
J Clin Pathol. 2013 Jul;66(7):620-2
pubmed: 23454726
Br J Sports Med. 2018 Apr;52(8):522-526
pubmed: 28798036
Eur J Clin Nutr. 2002 Jan;56(1):21-30
pubmed: 11840176
Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):669-684
pubmed: 30449548
J Am Soc Nephrol. 2010 Sep;21(9):1488-97
pubmed: 20595682
Minerva Endocrinol. 2019 Dec;44(4):344-350
pubmed: 31971357
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1133-1140
pubmed: 28187226
J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:132-7
pubmed: 24095930
J Clin Endocrinol Metab. 2015 Jun;100(6):2480-8
pubmed: 25856212
J Bone Miner Res. 2012 Jan;27(1):160-9
pubmed: 22028071
Lab Med. 2018 Mar 21;49(2):123-129
pubmed: 29346630
J Steroid Biochem Mol Biol. 2020 Oct;203:105751
pubmed: 32871238
Am J Clin Nutr. 2012 Jun;95(6):1350-6
pubmed: 22552038

Auteurs

José Luis Pérez-Castrillón (JL)

Internal Medicine Department, Hospital Universitario Río Hortega, Valladolid, Spain.
School of Medicine, Universidad de Valladolid, Valladolid, Spain.

Antonio Dueñas-Laita (A)

School of Medicine, Universidad de Valladolid, Valladolid, Spain.
Clinical Toxicology Unit, Hospital Universitario Río Hortega, Valladolid, Spain.

Maria Luisa Brandi (ML)

Dipartimento di Scienze Biomediche, Sperimentali e Cliniche "Mario Serio", Università degli Studi di Firenze, Florence, Italy.

Esteban Jódar (E)

Department of Endocrinology & Clinical Nutrition, Hospital Universitario Universitario Quironsalud Madrid, Madrid, Spain.
School of Health Sciences, Universidad Europea, Madrid, Spain.

Javier Del Pino-Montes (J)

School of Medicine, Universidad de Salamanca, Salamanca, Spain.
Rheumatology Department, Hospital Universitario de Salamanca, Salamanca, Spain.

José Manuel Quesada-Gómez (JM)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Hospital Universitario Reina Sofía, Córdoba, Spain.

Fernando Cereto Castro (F)

Internal Medicine Department, Hospital Quirón Barcelona, Barcelona, Spain.

Carlos Gómez-Alonso (C)

Bone Metabolism Unit, Hospital Universitario Central de Asturias - ISPA, Oviedo, Spain.

Laura Gallego López (L)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

José Manuel Olmos Martínez (JM)

Internal Medicine Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander, Spain.
School of Medicine, Universidad de Cantabria, Santander, Spain.

María Rosa Alhambra Expósito (MR)

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
Endocrinology and Nutrition Unit Hospital Universitario Reina Sofía, Córdoba, Spain.

Bernat Galarraga (B)

Rheumatology Department, Hospital Quirónsalud Bizkaia, Erandio, Spain.

Jesús González-Macías (J)

School of Medicine, Universidad de Cantabria, Santander, Spain.
Instituto de Investigación marqués de Valdecilla (IDIVAL), Santander, Spain.

Roger Bouillon (R)

Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.

Gonzalo Hernández-Herrero (G)

R&D and Innovation Department, Faes Farma, Leioa, Spain.

Nieves Fernández-Hernando (N)

R&D and Innovation Department, Faes Farma, Leioa, Spain.

Paula Arranz-Gutiérrez (P)

R&D and Innovation Department, Faes Farma, Leioa, Spain.

Sandra P Chinchilla (SP)

R&D and Innovation Department, Faes Farma, Leioa, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH